Next Phase Newsletter

A Silicon Valley-based VC fund is focused on early-stage ( Seed, Series A/B ) AI companies in Healthcare, Enterprise, and Automation. With a mission-driven thesis of doing well by doing good, the firm invest in technical founders keen on applying AI to solve some of the acutest problems faced across industries. The firm is currently investing from its second fund which is focusing on applied AI for Healthcare ( Precision Medicine, AI Drug Development, Gene/Cell Therapies Delivery, Oncology, Medical Imaging, Digital Healthcare), Enterprise ( Co-Pilots for Enterprise, Cybersecurity, DevOps/MLOps Tools, Infrastructure), and Automation ( Robotics, Autonomous Driving, Drones ). 

The firm’s team is a multidisciplinary team of seasoned founders, deep technologists/scientists, and healthcare practitioners united by a drive to nurture the next wave of startups transforming lives through AI. 

The firm can invest from Seed to Series B rounds with check size ranging from $250k-4M USD. The firm focuses on companies in the U.S., Canada, and the U.K. 
 
In terms of healthcare, the firm invests in companies that blend technology toward healthcare applications; what the firm likes to call “tech-bio”. Some examples include technology that can improve how drugs are discovered, targeted and delivered, that drive clinical results with biased-free patient selection and data transparency, digital therapeutics and precision medicine. The goal is to improve patient outcomes and serve multiple customers and pipelines. The firm is not interested in traditional assets. 
 
The firm prefers to take a board seat however, it is not required. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the US is particularly interested in tech companies generating data. The firm takes a close look at amount and quality of generated data. The firm is focused on early stages, specifically Seed and Series A. The firm’s typical check size is between $1M-$5M in equity, typically investing in 20 companies each year. The firm is focused on USA based companies. 
 
The firm is focused on digital health and techbio (typically looked at as the intersection of life sciences and AI). Previous investments include single-cell protein sequencing, a company using AI for tech-enabled drug discovery, and a company developing mRNA Therapeutics for Cancers. The firm has no revenue requirements for companies. 
 
The firm can both lead and co-invest and will consider a board seat on a case-by-case basis. The firm has no requirements for the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A newly established angel investor group headquartered in the US with ties/members in China is looking for innovative opportunities in the healthcare sector. The firm invest in early stages, including seed and series A, The firm’s typical check size ranges from $100K – $500K. The firm is open to USA based companies. 
 
The firm is primarily focused on investing in digital health and medical devices. The firm is indication- and modality- agnostic. 
 
The firm is open to both co-investing and leading, though prefers to co-invest. The firm likes with see a management team from a relevant domain with previous business experience. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A healthcare investment arm of a multi-strategy asset management firm focuses on early-stage opportunities in the medical device and digital health sectors, having invested approximately $250M USD in healthcare and medtech. The firm typically engages in Series A rounds and beyond, with check sizes ranging from $5M to $20M USD, and follow-on investments are a possibility. While the firm primarily focuses on the US (especially the Bay Area) and Europe, it remains open to global opportunities. 
 
The firm primarily considers opportunities in medical devices and digital health. Traditional asset-driven therapeutics are out of scope. The firm is agnostic to subsectors and indications but prefers disease areas with large addressable markets and companies with a clear reimbursement strategy. Some areas of interest include cardiovascular, ophthalmology, and diabetes. The fund typically evaluates clinical-stage opportunities but is open to considering design-stage companies, provided they have strong validation. 
 
The firm does not have specific requirements for a company’s founding team. However, the firm prefers founders with experience or a successful track record. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment firm manages funds for a major health insurance company in the US. The firm seeks to invest in healthcare companies of strategic interest to this insurance company while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe that are commercializing in the US or plan to in the near future. The firm also manages other funds that seek to invest in insurtech companies. The firm partners with payers and providers to drive innovation in healthcare, with a focus in medical devices, diagnostics, and AI solutions for providers. 
 
Within the healthcare space, the firm looks to invest across Healthcare IT, Services, Diagnostics, and Devices. 
 
The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and prefers to lead in rounds but can co-invest in certain circumstances. The firm generally looks to take a board seat following an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An early stage VC fund based in the US currently has $250M under management. The group focuses on highly technical, very early stage companies. The typical investment size is between $1M to $2M and they’re open to lead, co-lead and follow. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe. 

The firm have been highly active in deep tech/ R&D intensive investments, and have a significant biotech portfolio of notable/renowned companies in the industry. 
 
Currently, the firm’s team is focusing on Neuroscience and brain tech, like Neuromodulation, BCI, precision neuroscience, and infra from data driven angles, like AI in drug development, Multi Omics, from Seed to Series A. 
 
The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An early-stage venture capital firm headquartered in the US invests in life science and healthcare companies at Seed and potentially Series A stages. The firm also has the ability to incubate companies. The firm can act as a lead investor for the Seed round and can co-lead or follow for Series A. Typical check sizes range between USD $50k-500k. The firm is open to global companies but has a strong focus on the U.S. and Europe. 
 
The firm is mainly interested in therapeutics and is agnostic with modalities. The firm is opportunistic in terms of medical devices and life science tools. The firm is indication-agnostic. Companies of interest are typically in in-development or clinical trial stages. 
 
As the firm like to be hands on and are active investors, they prefer to take a board or observer seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.